Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Psychosom Res. 2011 Jun 30;71(5):349–356. doi: 10.1016/j.jpsychores.2011.05.003

Fig. 2.

Fig. 2

Percent categorical distributions of primary and intermediate clinical outcomes for entire sample (N=394). Baseline data is presented as there were no differences with individuals who were missing treatment week 24 data.

Note: SVR=Sustained Virologic Response; Tx24=Treatment Week 24 Virologic Response; RBV=Ribavirin Adherence; PEG=Peglyated Interferon Adherence; AE=Neuropsychiatric Adverse Events; DR=Dose Reductions Secondary to Neuropsychiatric Adverse Events; Stop=Discontinued Study Medications Early